Pralsetinib HCl (2097132-94-8 free base)
Pralsetinib is a potent and selective next-generation RET inhibitor effective against wild-type RET, key mutants (V804L, V804M, M918T), and CCDC6-RET fusions. Similarly, BLU-667 (pralsetinib) is a highly selective RET inhibitor targeting oncogenic fusions, mutations, and anticipated resistance variants. This small molecule is a valuable tool for in vitro biochemical assays and in vivo cancer model research targeting RET-driven pathologies.
Product Specifications
Field of Research
Pharmacology & Drug Discovery
Smiles
O=C ([C@@]1 (OC) CC[C@@H] (C2=NC (NC3=NNC (C) =C3) =CC (C) =N2) CC1) N[C@H] (C4=CC=C (N5N=CC (F) =C5) N=C4) C.[H]Cl
Molecular Formula
C27H33ClFN9O2
Molecular Weight
570.07
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041820-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400226-500 1x 500 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470826-100 1x 100 µL
Ep-CAM / CD326 (EGP40/826), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details